ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.98
0.86%
US Tech 100
20,877.20
1.72%
S&P 500
5,996.66
1.00%
US Dollar vs CAD
1.44664
-0.06%
Bitcoin
99,687.94
-1.31%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Silverback Therapeutics Inc (SBTX) Share Price

Silverback Therapeutics Inc

Silverback Therapeutics Inc (SBTX)

Skinbiotherapeutics Plc
5.87
0.00
(0.00%)
Closed January 19 3:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
5.87
Bid
2.37
Ask
6.15
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
563.502M
Previous Close
5.87
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
95,997,000
Dividend Yield
-
PE Ratio
-22.18
Earnings Per Share (EPS)
-0.57
Revenue
30k
Net Profit
-54.37M

About Silverback Therapeutics Inc

Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
ars-pharma.com
Headquarters
Wilmington, Delaware, USA
Founded
-

Ask ADVFN Intelligence (AI)

SBTX Latest News

More News

ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

Data to be Presented in Five Poster Presentations at the 2023 American Academy of Allergy, Asthma and Immunology Annual Meeting Data Support New Drug Application for neffy®, Currently Under Review...

February 23 2023
GlobeNewswire Inc.

ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis

SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...

February 22 2023
GlobeNewswire Inc.

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...

February 09 2023
GlobeNewswire Inc.

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Data Support New Drug...

November 10 2022
GlobeNewswire Inc.

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy® in the U.S., if Approved neffy® NDA Currently Under...

November 08 2022
GlobeNewswire Inc.

Silverback Therapeutics' Nasal Spray for Allergic Reactions Gets FDA Review Approval

By Sabela Ojea Silverback Therapeutics Inc. said Friday that the U.S. Food and Drug Administration has accepted for review its new drug application for Neffy, an emergency nasal spray to treat...

October 21 2022
Dow Jones News

Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if approved Silverback Therapeutics, Inc. (Nasdaq:...

October 21 2022
Business Wire

Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

Transaction to support potential commercialization of neffy™, ARS’s needle-free epinephrine nasal spray Well-funded with at least three years of operating runway expected Companies to host...

July 21 2022
Business Wire

Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue...

May 17 2022
Business Wire

Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue...

May 12 2022
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

SBTX - Frequently Asked Questions (FAQ)

What is the current Silverback Therapeutics share price?
The current share price of Silverback Therapeutics is US$ 5.87
How many Silverback Therapeutics shares are in issue?
Silverback Therapeutics has 95,997,000 shares in issue
What is the market cap of Silverback Therapeutics?
The market capitalisation of Silverback Therapeutics is USD 563.5M
What is the 1 year trading range for Silverback Therapeutics share price?
Silverback Therapeutics has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Silverback Therapeutics?
The price to earnings ratio of Silverback Therapeutics is -22.18
What is the cash to sales ratio of Silverback Therapeutics?
The cash to sales ratio of Silverback Therapeutics is 41.87k
What is the reporting currency for Silverback Therapeutics?
Silverback Therapeutics reports financial results in USD
What is the latest annual turnover for Silverback Therapeutics?
The latest annual turnover of Silverback Therapeutics is USD 30k
What is the latest annual profit for Silverback Therapeutics?
The latest annual profit of Silverback Therapeutics is USD -54.37M
What is the registered address of Silverback Therapeutics?
The registered address for Silverback Therapeutics is 108 W. 13TH STREET, SUITE 100, WILMINGTON, DELAWARE, 19801
What is the Silverback Therapeutics website address?
The website address for Silverback Therapeutics is ars-pharma.com
Which industry sector does Silverback Therapeutics operate in?
Silverback Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BTCTBTC Digital Ltd
US$ 8.2697
(73.73%)
61.45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8.80
(62.36%)
18.63M
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
NUKKNukkleus Inc
US$ 29.97
(45.98%)
19.09M
GSITGSI Technology
US$ 3.97
(44.36%)
87.7M
DOGZDogness International Corporation
US$ 18.23
(-58.77%)
740.45k
ORKTOrangeKloud Technology Inc
US$ 3.02
(-24.88%)
21.08M
PMAXPowell Max Ltd
US$ 0.6364
(-23.31%)
4.17M
LGCBLinkage Global Inc
US$ 0.2876
(-22.27%)
890.66k
YYAIConnexa Sports Technologies Inc
US$ 0.8299
(-20.20%)
602.48k
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
GCTKGlucoTrack Inc
US$ 0.0852
(15.45%)
465.22M
RIMEAlgorhythm Holdings Inc
US$ 0.0406
(-4.02%)
387.23M
TGLTreasure Global Inc
US$ 0.2459
(14.75%)
267.1M
NVDANVIDIA Corporation
US$ 137.71
(3.10%)
201.4M

Discussion

View Full Feed
Zorax Zorax 2 minutes ago
Did you catch sortagreen's just previous post.
Not only is the fake coin, which shitface actually says in his ts swamp, that the coin isn't supposed to be used for trade. Yet an unbelievable amount of action is on chinese exchanges and some of the very people who invested in djt are on this
JerryCampbell JerryCampbell 3 minutes ago
Intraday executions ("tick data") for equities is available, but seriously expensive for a data feed. I'm not aware of any free sites.

Not sure what vendors would do with a request for a single equity. Never hurts to ask.

Now what if you want to go deeper than executed
NWBO
bar1080 bar1080 3 minutes ago
$96 billion in profits. Lord!
BRK.A
The Great Pumpkin The Great Pumpkin 4 minutes ago
Lebby the CEO didn’t even live in the same state as HQ. Who’s fault is that?

The problem was that LWLG was not operating well internally and the leading device engineers developing this technology apparently couldn't get the job done. There was no one in upper management making sure t
LWLG
fuagf fuagf 5 minutes ago
Hopefully we'll see some good, fresh, legitimate investigative stuff from all the right
people. We know we know some, and know there is more we don't know. We will.
Dorick Dorick 5 minutes ago
Mr. Bystander: Your defamatory allegations will be thoroughly contradicted by our dozens of very happy customers - but your own final words already prove how misinformed you are. Our velociraptor line bears no resemblance to any dog in the world. Some people have noticed that it does resemble the Au
FLCX
janice shell janice shell 6 minutes ago
In a Tesla that catches on fire, locking them inside as they fall to earth.
12yearplan 12yearplan 6 minutes ago
Good of Biden to 'parden' Garvey this morning'.. didnt know his significance fully until now.
[yt]-pmjF1vI7QY[/yt]
[yt]FDMCQR7A-dY[/yt]
MartinLutherKing MartinLutherKing 8 minutes ago
We must rise and shock the world once and for all
RNAZ
price_and_volume price_and_volume 8 minutes ago
That's a bit uncalled for tbh...
surprise-appearance clowns who don't know the options in a legal matter such as this...Another Chandra Pimp... trying to dissuade anyone from getting involved... Pu$$ies.... while our bashing experts explain their lack of legal knowledge to you, keep the faith
ENZC IES
jimr1717 jimr1717 10 minutes ago
🏆️ That’s why Tesla vehicles are engineered to be the safest cars in the world.

Model S, Model 3, Model X and Model Y have achieved among the lowest overall probability of injury of any vehicles ever tested by the U.S.

Here’s a collection Zzzzzzzzz
TSLA
janice shell janice shell 10 minutes ago
Yes, what Frum said was excellent. Absolutely on target.
Make It Jake Make It Jake 11 minutes ago
Current AIM-CASH weekly values

S&P 500 : 56.2% – A proxy for large- and mega-cap stocks
This is an increase from last week’s value. Percent rank : 89.4

S&P 400 : 60.5% – A proxy for mid-cap stocks
This is a decrease from last week’s value. Percent rank :
zooey zooey 12 minutes ago
At least it’s only 50 bucks man. You never know what could happen. I put 800 in at .0001. Good thing is, we double our money on every tick, if it moves..
GMPR
MartinLutherKing MartinLutherKing 12 minutes ago
We have been deep down in the dark for many years, investors lost everything 99.999% since IPO @ $150,000 a share
RNAZ
SorcererHero70 SorcererHero70 13 minutes ago
I don’t have the exact returns but based off my experience, you are correct with your assumptions. Leveraged etfs would be much easier. Also, the time decay on the LEAPs is more substantial than some realize. Also, there is often times problems with liquidity. From my experience I think letfs would
delerious1 delerious1 14 minutes ago
Not sure why anyone would want to disrespect the retail shareholders owning a micropenny stock on the OTC-Pink market...there are over 12,000 stocks on the OTC.....easy for the uneducated to call them all a "scam" but why punish the shareholders with contempt for something obviously misunderstood...
NBRI
Trend22 Trend22 15 minutes ago
WCVC - Commanders pulled it out last night. Still in the hunt!!
Brodey79 Brodey79 16 minutes ago
Wouldn’t that be somethin. Building something special here and anyone in now is in early. Lots of room for growth and easy to scale.
FDCT
12yearplan 12yearplan 16 minutes ago
That stream of consciousness I look forward .. at and in a different time.
TucsonPhil TucsonPhil 16 minutes ago
Rumors that Musk may buy Intel. Given the Twitter/X debacle, would that be good or bad?
INTC
ChannelTrader ChannelTrader 18 minutes ago
Good stuff, brother !
The Berry Brothers !!!!!

https://www.facebook.com/blakprophetz/videos/1137189684417966
fuagf fuagf 18 minutes ago
Sheesh. The guy just doesn't learn. His problem is his darts are so magically
conceived they tumble after hitting his target, react, and rebound onto him.

https://www.youtube.com/watch?v=ZgXNVA9ngx8
Tahoe2468 Tahoe2468 19 minutes ago
So they are saying they have a product already produced coming to the US made out of Coca leaves??? And also putting a "New age is coming" I don't know if we're supposed to play Blue clues or what? But obviously they put it in quotations for some reason..... 
KRTL
al44 al44 20 minutes ago
In a word yes-

If the races were reversed it would have already happened

https://media.gettr.com/group4/getter/2025/01/19/18/9d4ff744-3cc0-e84e-1cc3-57f4340b6835/e0c83bbb945e9263dcd66fea5877a545_768x0.jpg

Your Recent History

NASDAQ
SBTX
Silverback Therapeutics
AQSE
CRS.GB
Crystal Amber
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads